Papers
4
Total Citations
74
H-Index
3
About
Dr. Jiwoong Yu is a pioneering urologic surgeon and researcher whose work centers on improving surgical outcomes and risk stratification in urologic oncology. His most influential study, a 2015 investigation of neutrophil and lymphocyte counts as clinical markers for low-risk prostate cancer (50 citations), established a non-invasive, cost-effective tool for patient stratification, directly impacting clinical decision-making. Dr. Yu is at the forefront of robotic surgery innovation, as demonstrated by his 2024 propensity score-matched comparison of single-port versus multi-port robotic retroperitoneal partial nephrectomy (17 citations). This work, along with his comparison of robot-assisted versus laparoscopic adrenalectomy (4 citations), has advanced minimally invasive techniques, emphasizing reduced morbidity and enhanced recovery. Notably, he proposed the "RARC Tetrafecta" (3 citations), a novel standardization framework for early outcomes following robot-assisted radical cystectomy, aiming to set a new benchmark for surgical quality. With a growing portfolio that bridges biomarker discovery and surgical technology, Dr. Yu’s contributions are shaping the future of precision urologic care, offering tangible improvements in both diagnosis and treatment.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4